Program
Cyclophosphamide
Also written as “cyclophosphamide”, “Cyclophosphamide,Fludarabine” and “Cytoxan”.
Its studies are mostly in Breast Neoplasms · Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Non-Small-Cell Lung, led by 28 companies.
Drug pageCyclophosphamide: every studyMany companies study it; this page follows only the 70 they lead. All 1,538 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 151 open or running | phase 4since Jan 4, 2011 | Oct 16, 2007 | Feb 28, 2028phase 2 · NCT04931342 |
| Beijing Biotechits history only | 99 open or running | phase 2since Apr 5, 2026 | Mar 14, 2026 | Feb 18, 2027phase 1 · NCT07480941 |
| ImmunoVaccine Technologies, Inc. (IMV Inc.)its history only | 63 open or running | phase 2since Dec 12, 2014 | Dec 12, 2014 | none ahead |
| Amgenits history only | 40 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Sanofiits history only | 40 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Takedaits history only | 41 open or running | phase 2since Jul 25, 2007 | Jul 25, 2007 | none ahead |
| Allogene Therapeuticsits history only | 32 open or running | phase 2since Dec 8, 2022 | Dec 8, 2022 | Dec 2027phase 2 · NCT06500273 |
| Bristol-Myers Squibbits history only | 21 open or running | phase 2since Dec 22, 2016 | Dec 22, 2016 | Mar 15, 2029phase 1 · NCT07115745 |
| Hangzhou Huasai Biomedicineits history only | 22 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Aug 30, 2027phase 1 · NCT07105176 |
| Rampart Healthits history only | 21 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| Shanghai First Song Biotechnologyits history only | 21 open or running | early phase 1since Jul 30, 2024 | Jul 30, 2024 | none ahead |
| Adicet Therapeuticsits history only | 10 open or running | phase 1since Jan 26, 2021 | Jan 26, 2021 | none ahead |
| AryoGen Pharmedits history only | 10 open or running | phase 3since Nov 21, 2017 | Nov 21, 2017 | none ahead |
| Caribou Biosciencesits history only | 11 open or running | phase 1since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| CARsgen Therapeuticsits history only | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Criteriumits history only | 10 open or running | phase 1since Aug 7, 2012 | Aug 7, 2012 | none ahead |
| Gilead Sciencesits history only | 10 open or running | phase 1since Oct 13, 2017 | Oct 13, 2017 | none ahead |
| Merckits history only | 10 open or running | phase 2since Oct 23, 2008 | Oct 23, 2008 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 1since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| Neukio Biotherapeutics (Shanghai)its history only | 11 open or running | early phase 1since Aug 19, 2025 | Aug 19, 2025 | Jan 14, 2027early phase 1 · NCT07144462 |
| Nkartaits history only | 11 open or running | phase 1since Sep 25, 2020 | Sep 25, 2020 | none ahead |
| Oncotherapeuticsits history only | 10 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| Precision BioSciencesits history only | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| Sangamo Therapeuticsits history only | 10 open or running | phase 2since Aug 22, 2014 | Aug 22, 2014 | none ahead |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| Seah Lim M.D.its history only | 10 open or running | phase 2since Aug 29, 2012 | Aug 29, 2012 | none ahead |
| Shanghai Unicar-Therapy Bio-medicine Technologyits history only | 11 open or running | phase 1since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| TTY Biopharmits history only | 10 open or running | phase 2since Aug 31, 2010 | Aug 31, 2010 | none ahead |
Also a collaborator on its studies: Natera, Incyte, AbbVie and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2007First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT00545714 · 86 enrolled · Spain
- Jul 16, 2008Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT00718549 · 128 enrolled · Belarus, Poland
- Oct 15, 2008Phase 2 study in Breast NeoplasmsNCT00773695 · 150 enrolled · Norway
- Dec 17, 2010Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01263704 · 42 enrolled · Israel
- Jan 4, 20112 phase 4 studies in Leukemia, Lymphocytic, Chronic, B-CellNCT01271010, NCT01283386
- Feb 8, 2011Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01292603 · 240 enrolled · Argentina, Australia, Brazil and more
- Jul 23, 2012Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT01649856 · 572 enrolled · Algeria, Argentina, Belgium and more
- Feb 4, 2014Phase 2 study in Lymphoma, Non-HodgkinNCT02055820 · 267 enrolled · United States, Australia, Austria and more
- Mar 23, 2015Phase 4 study in Breast NeoplasmsNCT02419742 · 110 enrolled · India
- Aug 24, 2015Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02533401 · 34 enrolled · Argentina, Venezuela
- Nov 12, 2015Phase 1 study in Breast NeoplasmsNCT02605915 · 98 enrolled · United States
- Feb 23, 2016Phase 2 study in Arthritis, RheumatoidNCT02693210 · 161 enrolled · Australia, Belgium, Canada and more
- Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04790903 · 50 enrolled · United States, France, Italy and more
- Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
Ahead
- Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04931342
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 28, 2028 | 176 |
| NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 1 | Terminated | May 21, 2024 | 50 |
| NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Completed | Aug 2002 | 161 |
| NCT02605915Breast Neoplasms · United States | 1 | Completed | Nov 13, 2019 | 98 |
| NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela | 2 | Completed | Dec 2014 | 34 |
| NCT02419742Breast Neoplasms · India | 4 | Completed | Jun 24, 2021 | 110 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Jun 28, 2017 | 267 |
| NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more | 3 | Completed | Oct 21, 2014 | 572 |
| NCT01292603Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Brazil and more | 1 | Completed | May 7, 2014 | 240 |
| NCT01283386Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | Mar 16, 2016 | 26 |
| NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | May 4, 2016 | 89 |
| NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel | 2 | Completed | Apr 3, 2017 | 42 |
| NCT00773695Breast Neoplasms · Norway | 2 | Completed | Nov 9, 2022 | 150 |
| NCT00718549Leukemia, Lymphocytic, Chronic, B-Cell · Belarus, Poland | 3 | Completed | Sep 14, 2015 | 128 |
| NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain | 2 | Completed | May 20, 2016 | 86 |
How it is read
Names in the registry
- “Cyclophosphamide”, 74 entries
- “cyclophosphamide”, 9 entries
- “Cyclophosphamide,Fludarabine”, 4 entries
- “Cytoxan”, 3 entries
- “CHOP”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Multiple Myeloma, 11 studies
- Lymphoma, Large B-Cell, Diffuse, 9 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 8 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.